Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as an oral tablet for oral use. It is employed in the treatment of certain blood‑related cancers, particularly chronic lymphocytic leukemia and Hodgkin’s lymphoma, targeting rapidly dividing malignant cells.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of oncology treatment programs across multiple regions.

Leukeran (chlorambucil) is used in the management of lymphoid malignancies that rely on DNA replication for growth.

- Chronic lymphocytic leukemia: reduces leukemic cell proliferation and helps achieve remission or disease stabilization. - Hodgkin's lymphoma: contributes to tumor regression by inducing DNA cross‑linking in malignant Hodgkin cells. - Other lymphoid malignancies: provides therapeutic benefit in various non‑Hodgkin lymphomas and related blood cancers by targeting rapidly dividing cells.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach often occurring after dosing. - Fatigue: generalized tiredness that may affect daily activities. - Mild leukopenia: slight reduction in white blood cell count, usually detected on routine labs.

Serious or Rare Side Effects: - Severe bone marrow suppression: profound pancytopenia requiring medical intervention. - Infections: opportunistic bacterial, viral or fungal infections due to immunosuppression. - Secondary malignancies: rare development of new cancers such as myelodysplastic syndromes. - Pulmonary fibrosis: progressive scarring of lung tissue presenting with dyspnea.

Careful monitoring and specific measures are required to minimize risks associated with chlorambucil therapy. - Dose adjustment: required in patients with renal or hepatic impairment to avoid excess exposure. - Monitor blood counts: regular complete blood count testing to detect myelosuppression early. - Avoid in pregnancy: classified as Category D due to known teratogenic effects; contraindicated. - Use contraception: both male and female patients should employ effective contraception during treatment and for a defined period after. - Avoid live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk. - Store at ambient temperature: keep below 25°C, protect from moisture and light, and retain in original packaging.

Chlorambucil may interact with several drugs, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: additive bone marrow toxicity. - Combination with radiotherapy: increased risk of tissue damage and delayed healing. - Strong CYP2D6 inhibitors: may raise chlorambucil plasma levels, enhancing toxicity.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced immunosuppressive effect, requiring blood count surveillance. - Allopurinol: potential increase in myelosuppression risk. - Live attenuated vaccines: reduced efficacy and possible infection; assess timing relative to therapy.